Literature DB >> 2531841

Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.

V S Ganu1, H J Müller-Eberhard, T E Hugli.   

Abstract

C3f, a heptadeca-peptide having the amino acid sequence of NH2-Ser-Ser-Lys-Ile-Thr-His-Arg-Ile-His-Trp-Glu-Ser-Ala-Ser-Leu-Leu-Arg- COOH, is liberated during the catabolic degradation of C3b in serum. The amino acid sequence of C3f is known both from the cDNA-derived structure of C3 and from protein analysis after isolation of the natural factor. C3f was synthesized by solid phase peptide synthesis. Both natural and synthetic C3f had identical retention times by RP-18 high performance liquid chromatography (HPLC) analysis and the respective amino acid compositions agreed with the expected theoretical values. C3f, but not des-Arg-C3f, was weakly spasmogenic inducing contraction of guinea pig ileum at a level of 5-10 x 10(-6) M. Since C3f and C3a were cross-tachyphylactic, it was concluded that these two spasmogens compete for the same receptors. Both C3f and des-Arg-C3f at concns of 1-4 x 10(-4) M enhanced vascular permeability in guinea pig skin. These observations further suggest that C3f functionally resembles C3a anaphylatoxin. Formation of C3f in human serum following CVF activation of C3 could be demonstrated by radioimmunoassay (RIA). Digestion of C3f with purified human serum carboxypeptidase N produced C3f-desArg. These observations suggest that when serum complement protein C3 undergoes conversion to C3b, further degradation by Factors H and I readily generates C3f. C3f is a weak spasmogen that functions like C3a anaphylatoxin and C3f-desArg is a major metabolite in serum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531841     DOI: 10.1016/0161-5890(89)90112-0

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Properdin homeostasis requires turnover of the alternative complement pathway.

Authors:  Xiaobo Wu; Thomas Q Xu; John P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer.

Authors:  Jia Fan; Muy-Kheng M Tea; Chuan Yang; Li Ma; Qing H Meng; Tony Y Hu; Christian F Singer; Mauro Ferrari
Journal:  J Proteome Res       Date:  2016-04-26       Impact factor: 4.466

3.  Whole-genome sequencing study of serum peptide levels: the Atherosclerosis Risk in Communities study.

Authors:  Paul S de Vries; Bing Yu; Elena V Feofanova; Ginger A Metcalf; Michael R Brown; Atefeh L Zeighami; Xiaoming Liu; Donna M Muzny; Richard A Gibbs; Eric Boerwinkle; Alanna C Morrison
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

4.  The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma.

Authors:  Margarita Semis; Gabriel B Gugiu; Ellen A Bernstein; Kenneth E Bernstein; Markus Kalkum
Journal:  Anal Chem       Date:  2019-05-07       Impact factor: 6.986

5.  Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer.

Authors:  Yaojun Li; Yueguo Li; Tao Chen; Anna S Kuklina; Paul Bernard; Francisco J Esteva; Haifa Shen; Mauro Ferrari; Ye Hu
Journal:  Clin Chem       Date:  2013-10-21       Impact factor: 8.327

6.  The Pharmacogenetic Footprint of ACE Inhibition: A Population-Based Metabolomics Study.

Authors:  Elisabeth Altmaier; Cristina Menni; Margit Heier; Christa Meisinger; Barbara Thorand; Jan Quell; Michael Kobl; Werner Römisch-Margl; Ana M Valdes; Massimo Mangino; Melanie Waldenberger; Konstantin Strauch; Thomas Illig; Jerzy Adamski; Tim Spector; Christian Gieger; Karsten Suhre; Gabi Kastenmüller
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

7.  A novel blood-based biomarker for detection of autism spectrum disorders.

Authors:  N Momeni; J Bergquist; L Brudin; F Behnia; B Sivberg; M T Joghataei; B L Persson
Journal:  Transl Psychiatry       Date:  2012-03-13       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.